1715 URINARY SYMPTOMS AND SEXUAL DYSFUNCTION IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Silvia Proietti ◽  
Marilena Gubbiotti ◽  
Jacopo Adolfo Rossi de Vermandois ◽  
Massimo Porena ◽  
Antonella Giannantoni
2013 ◽  
Vol 12 (1) ◽  
pp. e303-e304 ◽  
Author(s):  
A. Giannantoni ◽  
S. Proietti ◽  
M. Gubbiotti ◽  
J.A. Rossi De Vermandois ◽  
M. Porena

2014 ◽  
Vol 11 (12) ◽  
pp. 2955-2965 ◽  
Author(s):  
Hélène Bisseriex ◽  
Amandine Guinet‐Lacoste ◽  
Marie Chevret‐Méasson ◽  
Pierre Costa ◽  
Samer Sheikh Ismael ◽  
...  

2007 ◽  
Vol 177 (4) ◽  
pp. 1438-1442 ◽  
Author(s):  
James P. Burke ◽  
Debra J. Jacobson ◽  
Michaela E. McGree ◽  
Ajay Nehra ◽  
Rosebud O. Roberts ◽  
...  

Author(s):  
Lee Shaughnessy ◽  
Mary Schuchman ◽  
Mohamed Ghumra ◽  
Patricia Daily ◽  
Jack S. Burks

2015 ◽  
Vol 73 (8) ◽  
pp. 681-687 ◽  
Author(s):  
Raquel Ataíde Peres da Silva ◽  
Guilherme Sciascia do Olival ◽  
Lívia Palma Stievano ◽  
Vania Balardin Toller ◽  
Sergio Semeraro Jordy ◽  
...  

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). These patients suffer from various comorbidities, including sexual dysfunction (SD). The lesions of MS may affect regions of the CNS along the pathway of sexual response. The Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19) is a scale that assesses sexual dysfunction. Adapt and validate the MSISQ-19 to Brazilian patients with MS. 204 individuals were evaluated, 134 patients with MS and 70 healthy persons for the control group. It was determined reproducibility, validity, internal consistency and sensitivity of the MSISQ-19-BR. Among patients with MS, 54.3% of male and 71.7% of female presented some kind of SD. In the control group the results were 12.5% and 19.5%, respectively. The MSISQ-19-BR is reproducible, reliable and valid for the Brazilian population and may be used as a tool for assessing the impact of sexual dysfunction in patients with MS.


2017 ◽  
Vol 372 ◽  
pp. 201
Author(s):  
Darija Kisic-Tepavcevic ◽  
Tatjana Pekmezovic ◽  
Goran Trajkovic ◽  
Nebojsa Stojsavljevic ◽  
Irena Dujmovic ◽  
...  

2008 ◽  
Vol 14 (8) ◽  
pp. 1131-1136 ◽  
Author(s):  
DK Tepavcevic ◽  
J Kostic ◽  
ID Basuroski ◽  
N Stojsavljevic ◽  
T Pekmezovic ◽  
...  

Objective Sexual dysfunction (SD) is a common but often overlooked symptom in multiple sclerosis (MS). The aim of this study was to estimate the frequency, type, and intensity of SD in our patients with MS and to investigate its influence on all the domains of quality of life. Methods The study population comprised a cohort of 109 patients with MS (McDonald's criteria, 2001). SD was quantified by a Szasz sexual functioning scale. Health-related quality of life was measured by a disease-specific instrument MSQoL-54 (Serbian version). Results The presence of at least one symptom of SD was found in about 84% of the men and in 85% of the women. The main complaints in women were reduced libido, difficulties in achieving orgasm, and decreased vaginal lubrication; in men, the main complaints were reduced libido, incomplete erections, and premature ejaculation. In women, statistically significant negative correlations between the presence and level of SD and quality of life domains were reached for all subscales ( P < 0.01), except for the Pain subscale ( P = 0.112). In men, negative correlations were also observed for all domains, but they were statistically significant for physical health, physical role limitations, social function, health distress, sexual function, and sexual function satisfaction ( P < 0.01). We found that the presence of all the analyzed types of sexual problems statistically significantly lowered scores on the sexual function and the sexual function satisfaction subscales in both men and women ( P < 0.01). The most prominent impact on both domains was observed for the total loss of erection in men and for anorgasmia in women. Conclusions Our results reveal that frequent occurrence of SD in MS patients prominently affects all aspects of their quality of life.


2020 ◽  
Vol 3 ◽  
pp. 66
Author(s):  
Hawra B. Al Dandan ◽  
Rose Galvin ◽  
Katie Robinson ◽  
Dorren McClurg ◽  
Susan Coote

Background: Neurogenic lower urinary tract dysfunction (NLUTD) is common among people with multiple sclerosis (MS) with a pooled prevalence of 68.41% using self-report measures and 63.95% using urodynamic studies. Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive option to manage bladder storage symptoms; however, the potential efficacy of TTNS among people with MS is based on a small number of studies with the absence of high-quality evidence relating to efficacy, and lack of clarity of the optimal electrical stimulation parameters and frequency, duration and number of treatment sessions. This study aims to assess whether TTNS is feasible and acceptable as a treatment for bladder storage symptoms in people with MS. Methods: We will use a single-arm experimental study to explore the feasibility and acceptability of TTNS in the treatment of bladder storage symptoms in MS. The CONSORT extension for pilot and feasibility studies will be followed to standardise the conduct and reporting of the study. The recruitment plan is twofold: 1) Open recruitment for people with MS through MS Ireland’s communication channels; 2) recruitment from a convenience sample of people with MS who have previously participated in a qualitative interview study of urinary symptoms. We will assess recruitment/retention rates, the urinary symptoms changes and the effect on quality of life pre and post intervention using ICIQ-OAB, 3-day bladder diary, King’s Health Questionnaire and collect self-reported data on adherence and adverse events. Acceptability of using TTNS will be evaluated at the end of intervention. This study has been reviewed and approved by the Education and Health Science’s Faculty Research Ethics Committee, University of Limerick [2020_06_07_EHS].  Conclusion: It is anticipated that assessing the feasibility and acceptability of TTNS for storage bladder symptoms in MS will inform the development of a definitive randomised trial. Trial registration: ClinicalTrials.gov NCT04528784 27/08/2020


Sign in / Sign up

Export Citation Format

Share Document